Industry Abstract Previews of #ACR22 The pharmaceutical companies will showcase their featured clinical trials and abstracts at #ACR22. These are their best studies for you to review and evaluate as part of your to-do list. https://t.co/8fBJmT1cXG https://t.co/r7H5sqELPo

• https://bit.ly/3NZtKLb

Abs 1417 finds physicians prefer ABA over TNFi for RF/ACPA+ pts w/ higher disease severity, older age, the presence of extra-articular manifestations, and comorbidities such as heart failure. My question: Trouble getting it first line? #ACR22 @RheumNow https://t.co/tlFMgjgDNM https://t.co/ukoeLgSSUd

• Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and Firs…

ATOM study, Abs 1314, greater proportion of men with OP on abaloparatide vs placebo met the definition of a >3% responder at the LS, TH, and FN. #ACR22 @RheumNow https://t.co/q6gcX5Azts https://t.co/WEjqbl14ZN

• Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Densi…

#Abstr 1609 - comorbidity clusters in pts with #AS and association w/ disease activity and functional impairment using PSOAS cohort - identified 5 clusters based on comorbidity - Depression cluster --> ↑ disease activity and fxnl impairment @RheumNow #ACR22 https://t.co/cGz4vpOGJ9

Glucocorticoids ≤5 mg/d did not seem to be associated with a reduction of BMD in patients with iRMD and current or prior exposure to GC. Abs 1319 #ACR22 @RheumNow https://t.co/xbYW9y522I https://t.co/QQVjVXoFNf

• Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on B…

Abs 1307 at #ACR22 Romo did not negatively impact knee OA pain or function in postmenopausal women with OP. @RheumNow https://t.co/VMkUnwWt4v https://t.co/fTRPo25GZm

• Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results…

PC4d≥10 MFI is associated with thrombosis in SLE and predicts future arterial thrombosis. Abs 1442 #ACR22 @RheumNow https://t.co/zg7rrOSALs https://t.co/Hs2eOa2vxJ

• Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk …

In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO

• Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etan…

Numerically, SLE was more common in cITP patients. Risks include +ANA and female sex. Abs 1461 #ACR22 @RheumNow https://t.co/0kyqlVphac https://t.co/HfYKCMybdL

• The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocy…

While myositis in the setting of SLE was found to be around 5% in Abs 1453, it was not associated with mortality. #ACR22 @RheumNow https://t.co/hLLuYoXsCv https://t.co/44XGhbPxzW

• Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus …

DAVIX is a promising surrogate outcome measure of vascular disease in SSc. Questions around cost and access remain. Abs 1541 #ACR22 @RheumNow https://t.co/KJgtcG5ah8 https://t.co/NsK7b8fQFt

• MRI Digital Artery Volume Index (DAVIX) Predicts Future Digital Ulcers and Dise…

@RheumNow video from #ACR22 Opioid use in PsA and SpA patients Discussing abstract 1012 by @AlexisOgdie https://t.co/fKRog1aIkH

Out work showing JIA pts with sharp decline in needing TKAs, however increased TKA utilizations for tumors!! We are treating inflammatory arthritis better over timein the pediatric population...Natiowide data over 15 years! #ACR22 @Rheumnow abst# 0843 https://t.co/inw41Y1o9r

• https://twitter.com/HSpecialSurgery/status/1591823215323586561

TONIGHT! Join us! #ACR22 https://t.co/P0HHEl19hH https://t.co/zjfoNrlYGk

• https://bit.ly/3A9diSG